Italy In-Vitro Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Italy In-Vitro Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Italy in-vitro diagnostics market is expected to grow at a CAGR of 7.5% over the forecast period (2022-2027).

The ongoing Covid-19 pandemic impacted the studied market significantly. During the initial phase of the pandemic due to the lockdowns and shutdowns, the market was impacted adversely. For instance, the research article “Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario” published in April 2022 mentioned that when the multicenter study was conducted in Italy, the lung cancer patients were found to be vulnerable as a result of the decline in new diagnoses and the transition to an earlier stage of diagnosis for the target population during the initial phase. However, owing to the increasing demand for testing and diagnosis of Covid-19 infection, and increasing cases of chronic disease in Italy, the in-vitro diagnostics market is predicted to witness steady growth. Thus, the pandemic is expected to have a considerable impact on the market studied.

Factors such as the rising prevalence of chronic diseases and the increasing use of point-of-care (POC) diagnostics are major factors that are anticipated to drive market growth over the forecast period. For instance, the article titled "Cardiovascular disease (CVD) burden: Italian and global perspectives" published in Europe PMC, in March 2021, stated that Italy has an almost two-fold greater cardiovascular disease (CVDs) prevalence than the rest of the world (12.9% vs. 6.6%), while age-standardized figures are nearly similar (6.2% vs. 6.3%). Hence, the country's demand for early diagnostics for disease detection is expected to increase. And this is anticipated to drive the in-vitro diagnostics, driving the market growth in the country.

Moreover, the major players in the country are actively focused on the innovation of technically advanced products which can be beneficial to the target population in the country for disease detection and treatment. For instance, in May 2022, Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, and Dante Labs, a company developing genomics and precision medicine partnered for the commercialization of ColoAlert in Italy and the United Arab Emirates (UAE). ColoAlert is an effective and easy-to-use at-home detection test for colorectal cancer (CRC). Thus, such developments are anticipated to fuel market growth in the country.

Therefore, the increasing chronic diseases in the country and the availability of technically advanced products are expected to boost the in-vitro diagnostics market in Italy. However, the strict regulations applied to the diagnostic products are expected to hinder market growth over the studied period.

Key Market TrendsMolecular Diagnostics Segment is Anticipated to Witness Growth Over the Forecast Period

Molecular diagnostic devices are used to analyze biological markers in the genome and proteome to detect pathogens or mutations. Based on the technology used, molecular diagnostic devices can be segmented into chips and microarrays, mass spectroscopy, next-generation sequencing (NGS), polymerase chain reaction (PCR)-based methods, cytogenetics, and molecular imaging. Factors, such as large outbreaks of bacterial and viral epidemics in Italy, increasing demand for point-of-care diagnostics, and rapidly evolving technology, are driving the growth of the molecular diagnostics segment.

The Covid-19 pandemic impacted the segment growth significantly. During the pandemic, molecular diagnostic tests were adopted by researchers in Italy. For instance, the Logix Smart COVID-19 Test Kit was used by Italian researchers to confirm the presence of SARS-CoV-2, including mutated strains of the virus, in a community surveillance method of testing single-use waste, as per the press release published in September 2021 by Co-Diagnostics, Inc., a molecular diagnostics company. Thus, the adoption of molecular diagnostics during the pandemic increased in Italy. Which is further expected to fuel the segment growth.

Moreover, advancements in molecular diagnostics followed by new product launches, and continuous engagement of the major players in the molecular diagnostics segment are one of the major factors driving the growth of the segment in Italy. For instance, in October 2021, ELITechGroup, an Italy-based company focused on manufacturing and distribution of diagnostic solutions to laboratories, launched the new CE-IVD stand-alone “Sample – to – Result” real-time (RT) PCR solution namely ELITe BeGenius. The product makes molecular biology universally accessible with its compact footprint, ease of use, and total automation. The company also offers ELITe InGenius and ELITe BeGenius molecular diagnostics instruments to every lab, including those who are newly starting with molecular testing. Such developments in the segment are expected to contribute to the segment growth over the forecast period.

Therefore, owing to the aforementioned factors the segment is anticipated to witness growth over the forecast period.

Competitive Landscape

The in-vitro diagnostics market in Italy is competitive due to presence of many global players. Moreover, some domestic players have also been competing in the Italian market. These factors have made the region very competitive. Some of the market players in the market are Abbott Laboratories, Becton, Dickinson and Company, BioMerieux, Bio-Rad Laboratories, Inc., Danaher, F. Hoffmann-La Roche AG, DIESSE Diagnostica Senese Società Benefit SpA, and SCLAVO Diagnostics International, among others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.